SCHEMBL3055295

SCHEMBL3055295

COc1cccc(CN2Cc3cc(OC)c(O)cc3CC2(C)C)c1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DHCR7 Q9UBM7 3/20 0.58
DRD4 P21917 2/20 0.43
DRD3 P35462 2/20 0.43
DRD2 P14416 1/20 0.42
TMEM97 Q5BJF2 1/20 0.42
SIGMAR1 Q99720 1/20 0.41
ACHE P22303 1/20 0.41
KDM4E B2RXH2 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
CMA1 P23946 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
ABCB1 P08183 1/20 0.39
LPO P22079 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3051222 0.84 CA2 (0.46) DHCR7TMEM97SIGMAR1KDM4ECMA1
SCHEMBL3054963 0.81 CA9 (0.60) DHCR7DRD3DRD2KDM4ETDP1
SCHEMBL3052607 0.78 DHCR7 (0.48) DHCR7DRD3DRD2SIGMAR1ACHE
SCHEMBL3052036 0.77 DHCR7 (0.80) DHCR7DRD4DRD3DRD2TMEM97
SCHEMBL3054533 0.76 DHCR7 (0.70) DHCR7DRD4DRD3DRD2TMEM97
SCHEMBL3050133 0.76 DHCR7 (0.55) DHCR7DRD4DRD3DRD2TMEM97
SCHEMBL3058753 0.74 DHCR7 (0.53) DHCR7DRD4DRD3DRD2TMEM97
SCHEMBL14739911 0.73 DHCR7 (1.00) DHCR7DRD4DRD3DRD2TMEM97
SCHEMBL6821495 0.71 ALDH1A1 (0.43) DRD4TMEM97SIGMAR1ACHEKDM4E
SCHEMBL3055394 0.70 DHCR7 (0.54) DHCR7DRD4DRD3DRD2TMEM97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222299-A1 COMPOUND STERIX LIMITED (GB) 2010-09-02 US claimed
EP-2155192-B1 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS STERIX LTD (GB) 2016-09-28 EP disclosed
US-8394825-B2 Compound STERIX LIMITED (GB) 2013-03-12 US disclosed
US-20100222299-A1 COMPOUND STERIX LIMITED (GB) 2010-09-02 US disclosed
EP-2155192-A2 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS Sterix Limited (GB) 2010-02-24 EP disclosed
WO-2008117061-A2 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS STERIX LIMITED (GB) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222299-A1 COMPOUND MKI67, VHL, MYC DHCR7 421/4885DRD4 1675/4885DRD3 3408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.